ARTICLE | Company News
DNAPrint, Proteos Inc. deal
June 20, 2005 7:00 AM UTC
Proteos, a CRO, will manufacture preclinical batches of DNAP's PT-401 erythropoietin (EPO) dimer to treat anemia. In April, DNAP acquired an exclusive worldwide license to the compound from Beth Israe...